Company: LENZ
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001815776-25-000032
Chunk: 346

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 8
Chunk 346
---
):Fair Value Measurements at Reporting DateTotalLevel 1Level 2Level 3At March 31, 2025:Cash equivalentsMoney market funds$21,973 $21,973 $— $— Corporate debt securities647 — 647 $— Total cash equivalents measured at fair value$22,620 $21,973 $647 $— Marketable securitiesCommercial paper$51,933 $— $51,933 $— U.S. treasury securities48,851 48,851 — — Corporate debt securities44,928 — 44,928 — U.S. government agency securities25,222 — 25,222 — Total marketable securities measured at fair value$170,934 $48,851 $122,083 $— At December 31, 2024:Cash equivalentsMoney market funds$17,693 $17,693 $— $— U.S. government securities999 — 999 — U.S. treasury securities997 997 — — Total cash equivalents measured at fair value$19,689 $18,690 $999 $— Marketable securitiesCommercial paper$58,823 $— $58,823 $— U.S. treasury securities46,309 46,309 — — Corporate debt securities43,669 — 43,669 — U.S. government agency securities40,071 — 40,071 — Total marketable securities measured at fair value$188,872 $46,309 $142,563 $— The following table presents the amortized cost and estimated fair market value of our cash equivalents and marketable securities as of the dates presented (in thousands):March 31, 2025Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$21,973 $— $— $21,973 Corporate debt securities646 1 — 647 Marketable securities:Commercial paper$51,926 $24 $(17)$51,933 U.S. treasury securities48,785 66 — 48,851 Corporate debt securities44,898 33 (3)44,928 U.S. government agency securities25,203 21